Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | SORT1 | Q99523 | 14/20 | 0.58 |
| ▸ | CES2 | O00748 | 2/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.49 |
| ▸ | RXRA | P19793 | 1/20 | 0.49 |
| ▸ | RXRB | P28702 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21852902 | 0.90 | CES2 (0.55) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL460066 | 0.88 | KDM4E (0.69) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL12897775 | 0.86 | ALDH1A1 (0.46) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL9541475 | 0.84 | ALDH1A1 (0.59) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL17637938 | 0.82 | TDP1 (0.44) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL30184263 | 0.81 | KDM4E (0.66) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL424990 | 0.81 | RXRB (0.70) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL18291815 | 0.81 | ALDH1A1 (0.56) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL30450981 | 0.81 | KDM4E (0.56) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL26732909 | 0.81 | KDM4E (0.56) | KDM4EALDH1A1HPGDHSD17B10USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021033141-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS PEST CONTROL AGENTS | PI INDUSTRIES LTD. (IN) | 2021-02-25 | — | — | WO | disclosed |
| WO-2020163673-A1 | INHIBITORS OF ADENYLATE-FORMING ENZYME MENE | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2020-08-13 | — | — | WO | disclosed |
| US-8618129-B2 | Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2013-12-31 | — | — | US | disclosed |
| EP-2611780-A1 | SUBSTITUTED 1-OXO-DIHYDROISOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012028300-A1 | SUBSTITUTED 1-OXO-DIHYDROISOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2012-03-08 | — | — | WO | disclosed |
| US-20120053203-A1 | Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as KCNQ2/3 modulators | GRUNENTHAL GMBH (DE) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053203-A1 | Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as KCNQ2/3 modulators | KCNQ1, KCNQ2, KCNQ3 | KDM4E 459/4885ALDH1A1 2009/4885HPGD 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.